Literature DB >> 19772429

A novel orthotopic mouse model of human anaplastic thyroid carcinoma.

Carmelo Nucera1, Matthew A Nehs, Michal Mekel, Xuefeng Zhang, Richard Hodin, Jack Lawler, Vânia Nose, Sareh Parangi.   

Abstract

BACKGROUND: Orthotopic mouse models of human cancer represent an important in vivo tool for drug testing and validation. Most of the human thyroid carcinoma cell lines used in orthotopic or subcutaneous models are likely of melanoma and colon cancer. Here, we report and characterize a novel orthotopic model of human thyroid carcinoma using a unique thyroid cancer cell line.
METHODS: We used the cell line 8505c, originated from a thyroid tumor histologically characterized by anaplastic carcinoma cell features. We injected 8505c cells engineered using a green fluorescent protein-positive lentiviral vector orthotopically into the thyroid of severe combined immunodeficient mice.
RESULTS: Orthotopic implantation with the 8505c cells produced thyroid tumors after 5 weeks, showing large neck masses, with histopathologic features of a high-grade neoplasm (anaplasia, necrosis, high mitotic and proliferative indexes, p53 positivity, extrathyroidal invasion, lymph node and distant metastases) and immunoprofile of follicular thyroid cell origin with positivity for thyroid transcription factor-1 and PAX8, and for cytokeratins.
CONCLUSIONS: Here we describe a novel orthotopic thyroid carcinoma model using 8505c cells. This model can prove to be a reliable and useful tool to investigate in vivo biological mechanisms determining thyroid cancer aggressiveness, and to test novel therapeutics for the treatment of refractory or advanced thyroid cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772429      PMCID: PMC2833178          DOI: 10.1089/thy.2009.0055

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  38 in total

1.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Selective activity of BS-RNase against anaplastic thyroid cancer.

Authors:  R Kotchetkov; J Cinatl; A A Krivtchik; J U Vogel; J Matousek; P Pouckova; B Kornhuber; D Schwabe; J Cinatl
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

Review 3.  Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation.

Authors:  T Kubota
Journal:  J Cell Biochem       Date:  1994-09       Impact factor: 4.429

4.  BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment.

Authors:  Shahnaz Begum; Eli Rosenbaum; Rui Henrique; Yoram Cohen; David Sidransky; William H Westra
Journal:  Mod Pathol       Date:  2004-11       Impact factor: 7.842

5.  Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data.

Authors:  T H Kuo; T Kubota; M Watanabe; T Furukawa; S Kase; H Tanino; Y Saikawa; K Ishibiki; M Kitajima; R M Hoffman
Journal:  Anticancer Res       Date:  1993 May-Jun       Impact factor: 2.480

Review 6.  Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis.

Authors:  R S Kerbel; I Cornil; D Theodorescu
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

7.  Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.

Authors:  Hidetoshi Sumimoto; Makoto Miyagishi; Hiroyuki Miyoshi; Shizuko Yamagata; Ayako Shimizu; Kazunari Taira; Yutaka Kawakami
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

8.  Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism.

Authors:  K Yoshimoto; H Iwahana; A Fukuda; T Sano; S Saito; M Itakura
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

Review 9.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.

Authors:  M C Bibby
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

10.  Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms.

Authors:  D Fabbro; C Di Loreto; C A Beltrami; A Belfiore; R Di Lauro; G Damante
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

View more
  45 in total

1.  A novel perfused Bloch-McConnell simulator for analyzing the accuracy of dynamic hyperpolarized MRS.

Authors:  Christopher M Walker; Yunyun Chen; Stephen Y Lai; James A Bankson
Journal:  Med Phys       Date:  2016-02       Impact factor: 4.071

2.  Bioluminescent human thyrospheres allow noninvasive detection of anaplastic thyroid cancer growth and metastases in vivo.

Authors:  Ashley N Reeb; Wen Li; Reigh-Yi Lin
Journal:  Thyroid       Date:  2014-05-20       Impact factor: 6.568

Review 3.  The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?

Authors:  Carmelo Nucera; Jack Lawler; Richard Hodin; Sareh Parangi
Journal:  Oncotarget       Date:  2010-12

4.  A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.

Authors:  Viswanath Gunda; Dennie T Frederick; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi
Journal:  Thyroid       Date:  2014-06-30       Impact factor: 6.568

Review 5.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

6.  The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.

Authors:  Pierre Vanden Borre; David G McFadden; Viswanath Gunda; Peter M Sadow; Shohreh Varmeh; Maria Bernasconi; Tyler Jacks; Sareh Parangi
Journal:  Thyroid       Date:  2014-01-24       Impact factor: 6.568

7.  Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma.

Authors:  Carrie C Lubitz; Tiannan Zhan; Viswanath Gunda; Salma Amin; Benjamin J Gigliotti; Abbey L Fingeret; Tammy M Holm; Heather Wachtel; Peter M Sadow; Lori J Wirth; Ryan J Sullivan; David J Panka; Sareh Parangi
Journal:  Thyroid       Date:  2018-02-27       Impact factor: 6.568

8.  Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.

Authors:  Yanlan Liu; Viswanath Gunda; Xi Zhu; Xiaoding Xu; Jun Wu; Diana Askhatova; Omid C Farokhzad; Sareh Parangi; Jinjun Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-24       Impact factor: 11.205

9.  Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.

Authors:  Viswanath Gunda; Alexandria P Cogdill; Maria J Bernasconi; Jennifer A Wargo; Sareh Parangi
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

Review 10.  Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF.

Authors:  Z A Antonello; C Nucera
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.